This inventor holds 3 USPTO granted patents. Top assignees: Ajinomoto Co., Ltd., Kazuo Sugamura, Other. Active years: 1996-1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 1996-1999
Title: Harumi Nakazawa: Innovator in Immunology
Introduction
Harumi Nakazawa is a prominent inventor based in Kawasaki, Japan. She has made significant contributions to the field of immunology, particularly through her innovative work on polypeptides that interact with human interleukin receptors. With a total of 3 patents, her research has the potential to impact medical treatments for various diseases.
Latest Patents
One of her latest patents involves a polypeptide that specifically binds to the .gamma.-chain of the human interleukin-2 receptor. This polypeptide selectively inhibits the binding of the .gamma.-chain to the .beta.-chain of the same receptor. The invention provides a method for blocking the human interleukin-2 response, which can be crucial in preventing graft rejection after transplantation. Additionally, it can be used to treat inflammatory diseases, including allergic and autoimmune disorders. Another patent focuses on peptides that inhibit the binding of human IL-6 to its receptor, offering potential treatments for diseases exacerbated by IL-6.
Career Highlights
Throughout her career, Harumi Nakazawa has worked with notable companies, including Ajinomoto Co., Ltd. and Kazuo Sugamura. Her work has been instrumental in advancing the understanding of immunological responses and developing new therapeutic strategies.
Collaborations
Harumi has collaborated with esteemed colleagues such as Toshiro Shimamura and Junji Hamuro. These partnerships have further enriched her research and contributed to her innovative discoveries.
Conclusion
Harumi Nakazawa's contributions to immunology through her patents and collaborations highlight her role as a leading inventor in the field. Her work continues to pave the way for advancements in medical treatments and therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile